Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
Nautilus Biotechnology, Inc. roe for the quarter ending 2026-06-30 was -43.11%, a change of -6.84% year-over-year.
Nautilus Biotechnology, Inc. roe for the quarter ending 2026-03-31 was -39.53%, a change of -4.21% year-over-year.
Nautilus Biotechnology, Inc. roe for the quarter ending 2025-12-31 was -37.59%, a change of -3.68% year-over-year.
Nautilus Biotechnology, Inc. roe for the quarter ending 2025-09-30 was -37.14%, a change of -5.71% year-over-year.
Nautilus Biotechnology, Inc. roe for fiscal 2025 was -37.59%, a change of -3.68% from fiscal 2024.
Nautilus Biotechnology, Inc. roe for fiscal 2024 was -33.91%, a change of -9.91% from fiscal 2023.
Nautilus Biotechnology, Inc. roe for fiscal 2023 was -24.00%, a change of -5.60% from fiscal 2022.
Nautilus Biotechnology, Inc. roe for fiscal 2022 was -18.39%, a change of -4.55% from fiscal 2021.